The $7.25 Billion Roundup Settlement Goes Before Judge Boyer on Monday at 9:30 a.m. — No Ruling Is Expected That Day, Registration Does Not Open, and the Opt-Out Deadline Was June 4, Not the August 21 Date Everyone Repeats.

A fairness hearing is the step at which a judge decides whether a class settlement is fair, reasonable and adequate, and whether to make it binding on everyone who did not opt out. It is not a trial and it is not a distribution. Reuters' Dietrich Knauth, previewing the hearing on September 11, wrote that Judge Boyer “is not expected to issue an immediate ruling at the hearing,” and a Monsanto spokesman told him the company believes the settlement “is fair to all parties and warrants final approval.” The official settlement site, run by BrownGreer, is blunter: “Registration and Claim Submission are not available right now, as the Court has not yet granted final approval of the settlement.”

If approval comes, the site's own sequence is: people already diagnosed with non-Hodgkin lymphoma get 180 days after final approval to register, then file a claim “within 180 days after any appeals are resolved”; people diagnosed later “file a claim within 6 years of diagnosis or before the 16th Annual Payment Date.” That “16th Annual Payment Date” is the tell about the structure — this is a program that “will pay claims for 17 to 21 years,” not a fund that writes checks next spring. Anyone who tells you Roundup money is arriving this year is describing a step that has not happened and, by the settlement's own design, cannot happen quickly.

The August 6, 2026 order is two pages, signed by Judge Boyer, ruling on a “Joint Motion to Continue Fairness Hearing and Opt Out Challenge Response Deadline” filed by class counsel and Monsanto together. Its reasoning is in one sentence: “The Court acknowledges that, pursuant to its order of July 13, 2026, a significant number of challenges to the validity or invalidity of opt out requests have been filed with the Court.” The court wanted “resolution of those issues before the Court conducts the Fairness Hearing,” referred unresolved challenges to the special master, and moved the hearing “to September 14, 2026, at 9:30am.” The last sentence is the one that has been misread: “The deadline set for responding to challenges regarding the validity or invalidity of opt out requests shall be continued to August 21, 2026.”

That is a deadline for lawyers to answer challenges to opt-outs that were already on file. It is not an opt-out deadline. The official site lists the Opt Out Deadline and the Objection Deadline as the same day: June 4, 2026. Two of our own tracker pages carried “21 August 2026 — the opt-out deadline passes” until this morning, while two neighbouring pages had June 4 right; all four now agree with the court. Nobody could opt out on August 21, and nobody can opt out now.

Why so many challenges? The Supreme Court decided Monsanto Co. v. Durnell on June 25, 2026 — three weeks after the opt-out deadline — holding 7–2 that federal pesticide labeling law preempts state failure-to-warn claims against Roundup. Law-firm trackers describe a summer in which people who had opted out asked to come back in, and the court's own order confirms that the validity of individual opt-out elections became the contested question. On a separate track, objectors tried to move the settlement decision into federal court; according to law-firm trackers, Judge Henry Autrey of the Eastern District of Missouri sent it back to state court in June and the Eighth Circuit dismissed the objectors' appeal on August 27. We have not seen either order ourselves and cite those reports as such.

The settlement site's “Learn More” page publishes the award structure, and it is more specific than the “$6,000 to $165,000+” on the home page. Two things drive the number: whether you were exposed at work or at home, and how old you were at diagnosis.

Occupational claimants — farmers, farm laborers, landscapers, groundskeepers, applicators, highway and rail maintenance workers and the like — qualify if they were “exposed to Roundup Products for more than 80 hours” in an agricultural, industrial, turf or ornamental job and “earned more than 50% of your income or more than $15,000 from this job in at least one year,” with documentary proof such as payroll or tax records. Estimated award range: $60,000 to $165,000; no quick-pay option. Residential claimants — everyone else who used the product — get an estimated $20,000 to $40,000, or a quick-pay of $7,700 to $14,500 “if you prefer not to wait for full program processing.” Anyone diagnosed at age 78 or older is in a separate row: $10,000 program award, $6,000 quick-pay. That last cell is the reconciliation: Reuters' “$10,000 to $165,000” is the range of program awards; the site's “$6,000” is the quick-pay floor for the oldest claimants. Both are right about different columns.

The class is broader than the claimants. Subclass 1 is everyone “diagnosed with non-Hodgkin lymphoma (NHL) as of March 4, 2026” who meets the exposure test; Subclass 2 is everyone exposed in the U.S. before February 17, 2026 who has not been diagnosed — “You are part of the settlement now, but you can only submit a claim for compensation if you are diagnosed with NHL in the future.” Immigration status does not matter. Extra payments exist for “extraordinary circumstances,” heavy home use and extreme hardship. And the $7.25 billion is “up to”: Reuters counts roughly 65,000 current claims in state and federal courts, so if every one of them drew from the cap it would work out to about $111,500 each — but the program is built to pay people diagnosed over the next sixteen years as well, so that arithmetic is a ceiling on the pot, not a forecast for any claimant. Attorney's fees and medical liens come off individual awards before anything is paid out.

Christopher Seeger, who would represent current claimants, said when the deal was announced on February 17, 2026 that it was designed so today's and tomorrow's patients “have access to meaningful compensation,” per the Associated Press. On the other side, attorney Matt Clement, who the AP says represents about 280 plaintiffs, called the proposed payouts “exceedingly too small,” and Reuters summarizes the objectors' position as arguing that clients “should not be pushed into” the framework. That is the argument Judge Boyer hears Monday.

The context Bayer brings to the courtroom: a 2020 settlement of roughly $10 billion resolved most then-pending cases but left the company exposed to future ones, which is the gap this class deal is built to close; the June Durnell ruling narrowed the legal path for new individual suits; and, per the Associated Press, the company has already removed glyphosate from Roundup sold for U.S. residential lawns, while denying that the chemical causes cancer. The settlement includes no admission of liability, and a payment under it will not be a finding that Roundup caused anyone's lymphoma — the science remains contested between IARC's 2015 “probably carcinogenic” classification and the EPA's 2017 finding of no likely risk at expected exposures. What happens after Monday rests with the judge; if he approves, appeals could delay payments further, and the site's 180-day registration clock only starts at final approval. We will update our trackers when an order is entered.